Investigational drug · Phase 2
FT839
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Rheumatoid Arthritis (RA).
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "FT839"
First trial start
2026
Oct 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "FT839", any sponsor or status.
Conditions studied
As listed on its trial records.
- ANCA-Associated Vasculitis (AAV)
- Idiopathic Inflammatory Myositis (IIM)
- Rheumatoid Arthritis (RA)
- Systemic Lupus Erythematosus (SLE)
- Systemic Sclerosis (SSc)
Approved drugs for the same conditions: Rheumatoid arthritis · Lupus (SLE) · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "FT839" as an intervention, largest first.
- FT839 in Autoimmune DiseasesRecruiting
Fate TherapeuticsIndustry
NCT07800871 · 446 participants (planned) · Start Oct 2026 · Primary completion Oct 2028
Drug: FT839 · For: ANCA-Associated Vasculitis (AAV); Idiopathic Inflammatory Myositis (IIM); Rheumatoid Arthritis (RA) and 2 more
Sites: Fullerton, California
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for ANCA-Associated Vasculitis (AAV)
- Descartes-08Phase 24 trials
Cartesian Therapeutics · Myasthenia Gravis, Generalized, Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.